CA2155329A1 - Acylfulvene analogues as antitumor agents - Google Patents
Acylfulvene analogues as antitumor agentsInfo
- Publication number
- CA2155329A1 CA2155329A1 CA002155329A CA2155329A CA2155329A1 CA 2155329 A1 CA2155329 A1 CA 2155329A1 CA 002155329 A CA002155329 A CA 002155329A CA 2155329 A CA2155329 A CA 2155329A CA 2155329 A1 CA2155329 A1 CA 2155329A1
- Authority
- CA
- Canada
- Prior art keywords
- acylfulvene
- analogues
- antitumor agents
- subject
- cell growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/455—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
- C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/683—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
- C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
- C07C49/737—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Abstract
A method of inhibiting tumor cell growth in a subject is provided comprising contacting the tumor with a therapeutic amount of an acylfulvene analog having structure (I), wherein die analog is capable of inhibiting tumor cell growth without excessive toxicity to the subject and wherein R is (a), where R1= alkyl, aryl, NH2, NHR, or NR2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/015,179 US5439936A (en) | 1989-10-03 | 1993-02-09 | Method of treating certain tumors using illudin analogs |
US08/015,179 | 1993-02-09 | ||
PCT/US1994/001232 WO1994018151A1 (en) | 1993-02-09 | 1994-02-02 | Acylfulvene analogues as antitumor agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2155329A1 true CA2155329A1 (en) | 1994-08-18 |
CA2155329C CA2155329C (en) | 2006-08-15 |
Family
ID=21769946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002155329A Expired - Fee Related CA2155329C (en) | 1993-02-09 | 1994-02-02 | Acylfulvene analogues as antitumor agents |
Country Status (22)
Country | Link |
---|---|
US (3) | US5439936A (en) |
EP (1) | EP0683762B1 (en) |
JP (1) | JP3908270B2 (en) |
KR (1) | KR100311327B1 (en) |
CN (1) | CN1046934C (en) |
AT (1) | ATE174894T1 (en) |
AU (1) | AU676889B2 (en) |
BR (1) | BR9405689A (en) |
CA (1) | CA2155329C (en) |
CZ (1) | CZ288596B6 (en) |
DE (1) | DE69415507T2 (en) |
DK (1) | DK0683762T3 (en) |
ES (1) | ES2125441T3 (en) |
GR (1) | GR3029736T3 (en) |
HU (1) | HU220059B (en) |
MD (1) | MD1418G2 (en) |
NO (1) | NO318648B1 (en) |
NZ (1) | NZ262282A (en) |
PL (1) | PL175024B1 (en) |
RU (1) | RU2145849C1 (en) |
TJ (1) | TJ266B (en) |
WO (1) | WO1994018151A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932553A (en) * | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
US5723632A (en) | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
US7141603B2 (en) * | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
US6025328A (en) * | 1998-02-20 | 2000-02-15 | The Regents Of The University Of California | Antitumor agents |
US6436916B1 (en) | 2000-10-12 | 2002-08-20 | Alvin Guttag | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs |
US7015247B2 (en) * | 2000-10-12 | 2006-03-21 | Alvin Guttag | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
US7655695B2 (en) * | 2005-08-03 | 2010-02-02 | The Regents Of The University Of California | Illudin analogs useful as anticancer agents |
WO2010085811A2 (en) * | 2009-01-26 | 2010-07-29 | Taipei Medical University | Use of pterosin compounds for treating diabetes and obesity |
US11135182B2 (en) | 2014-04-10 | 2021-10-05 | Af Chemicals, Llc | Affinity medicant conjugates |
US10285955B2 (en) | 2014-04-10 | 2019-05-14 | Af Chemicals, Llc | Affinity medicant conjugate |
CA2944699C (en) | 2014-04-10 | 2023-05-23 | Af Chemicals, Llc | Affinity medicant conjugates |
CN106083953A (en) * | 2016-06-15 | 2016-11-09 | 成都医学院 | A kind of from fiddlehead, extract former pteroside and the method preparing high purity raw pteroside |
WO2018170230A1 (en) * | 2017-03-15 | 2018-09-20 | Memorial Sloan Kettering Cancer Center | Diagnosis & treatment of ercc3-mutant cancer |
JP2021536492A (en) * | 2018-09-04 | 2021-12-27 | ランタン ファーマ インコーポレイテッド | Illudin analogs, their use, and how to synthesize them |
US11160807B1 (en) | 2018-12-11 | 2021-11-02 | Af Chemicals, Llc | Methods, compositions and devices for treating cancer with illudofulvenes |
RU2738848C1 (en) * | 2019-10-24 | 2020-12-17 | Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") | Hepatitis b virus (hbv) inhibitor, which is a derivative of n-{3-[6-(dialkylamino)pyridazine-3-yl]phenyl}aryl sulphonamide derivatives and derivatives of n-{4-[6-(dialkylamino)pyridazine-3-yl]phenyl}aryl sulphonamide |
US11591295B2 (en) | 2019-11-25 | 2023-02-28 | Af Chemicals Llc | Affinity illudofulvene conjugates |
EP4035684A1 (en) | 2019-11-25 | 2022-08-03 | AF Chemical LLC | Affinity illudofulvene conjugates |
CN112972443A (en) * | 2021-03-29 | 2021-06-18 | 杭州添帆生物科技有限公司 | Anticancer medicine and its application |
WO2023239821A2 (en) * | 2022-06-07 | 2023-12-14 | Lantern Pharma Inc. | Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib |
WO2024016014A2 (en) * | 2022-07-15 | 2024-01-18 | Lantern Pharma Inc. | Method for treating breast cancers and parp resistant breast cancers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6729590A (en) * | 1989-10-03 | 1991-04-28 | Regents Of The University Of California, The | Illudin analogs as anti-tumor agents |
GB9017024D0 (en) * | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
FI85318C (en) * | 1990-08-14 | 1992-03-25 | Tecnomen Oy | COMPENSATION AV FELET I EN KLOCKAS GAONG. |
JPH06223404A (en) * | 1993-01-25 | 1994-08-12 | Mitsubishi Kasei Corp | Optical information recording medium |
-
1993
- 1993-02-09 US US08/015,179 patent/US5439936A/en not_active Expired - Lifetime
-
1994
- 1994-02-02 AU AU61700/94A patent/AU676889B2/en not_active Ceased
- 1994-02-02 AT AT94908702T patent/ATE174894T1/en not_active IP Right Cessation
- 1994-02-02 BR BR9405689A patent/BR9405689A/en not_active Application Discontinuation
- 1994-02-02 TJ TJ96000336A patent/TJ266B/en unknown
- 1994-02-02 WO PCT/US1994/001232 patent/WO1994018151A1/en active IP Right Grant
- 1994-02-02 KR KR1019950703280A patent/KR100311327B1/en not_active IP Right Cessation
- 1994-02-02 HU HU9502358A patent/HU220059B/en not_active IP Right Cessation
- 1994-02-02 PL PL94310159A patent/PL175024B1/en not_active IP Right Cessation
- 1994-02-02 CN CN94191560A patent/CN1046934C/en not_active Expired - Fee Related
- 1994-02-02 MD MD96-0212A patent/MD1418G2/en not_active IP Right Cessation
- 1994-02-02 CZ CZ19951986A patent/CZ288596B6/en not_active IP Right Cessation
- 1994-02-02 EP EP94908702A patent/EP0683762B1/en not_active Expired - Lifetime
- 1994-02-02 CA CA002155329A patent/CA2155329C/en not_active Expired - Fee Related
- 1994-02-02 NZ NZ262282A patent/NZ262282A/en not_active IP Right Cessation
- 1994-02-02 JP JP51820894A patent/JP3908270B2/en not_active Expired - Fee Related
- 1994-02-02 DE DE69415507T patent/DE69415507T2/en not_active Expired - Lifetime
- 1994-02-02 ES ES94908702T patent/ES2125441T3/en not_active Expired - Lifetime
- 1994-02-02 DK DK94908702T patent/DK0683762T3/en active
- 1994-02-02 RU RU95121694A patent/RU2145849C1/en not_active IP Right Cessation
- 1994-07-15 US US08/276,169 patent/US5563176A/en not_active Expired - Lifetime
- 1994-11-01 US US08/332,940 patent/US5523490A/en not_active Expired - Lifetime
-
1995
- 1995-08-07 NO NO19953099A patent/NO318648B1/en not_active IP Right Cessation
-
1999
- 1999-03-19 GR GR990400821T patent/GR3029736T3/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2155329A1 (en) | Acylfulvene analogues as antitumor agents | |
CA2133963A1 (en) | Novel Mercaptoacetylamido Pyridazo[1,2]Pyridazine, Pyrazolo[1,2]Pyridazine, Pyridazo[1,2-a][1,2]Diazepine and Pyrazolo[1,2-a][1,2]Diazepine Derivatives Useful as Inhibitors of Enkephalinase and Ace | |
AU4636589A (en) | Tissue culture antiviral processes and compositions | |
IE43768L (en) | Oximes. | |
ES2009227A6 (en) | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents. | |
CA2153775A1 (en) | Potentiation of Temozolomide in Human Tumour Cells | |
EP0272914A3 (en) | 6-benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones | |
EP0350012A3 (en) | Antiviral composition | |
CA2067365A1 (en) | Illudin analogs as anti-tumor agents | |
IE862862L (en) | Peptides | |
CA2042556A1 (en) | Use of pervanadate as an inhibitor of phosphotyrosine phosphatase | |
CA2095659A1 (en) | Heteroatoms-containing tricyclic compounds | |
AU7584891A (en) | Treatment of osmotic disturbance with organic osmolytes | |
MY132057A (en) | Quinoxalinones, a process for their preparation and their use | |
BR8902344A (en) | COMPOSITION, PROCESS TO INHIBIT THE GROWTH OF MICROORGANISMS AND COMPOSITION OF SURFACE COATING | |
NZ241646A (en) | Cultivation of shellfish: seeding first type producing securement with second type not producing securement | |
ES8707553A1 (en) | Peptides. | |
AU2131988A (en) | Process for nitrification and nitrogen removal by nitrifying bacteria | |
CA2257581A1 (en) | Biodegradation of metal cyanides | |
CA2061995A1 (en) | Use of oxime ether derivatives for bioregulation in plants | |
AU3747489A (en) | Use of special amines to prevent nitrosamine formation | |
AU585279B2 (en) | Pesticidal biphenylyloxy and biphenylylalkoxy aryl acyl urea compounds | |
GB8700593D0 (en) | Deuterated l-arginine phosphate monohydrate | |
AU1485197A (en) | Diamines in the treatment of arrhythmia | |
AU7578091A (en) | Treatment of cachexia with interleukin 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |